[Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma].
In recent years, the chemotherapy of non-small cell lung cancer (NSCLC) has almost been reached a platform stage, and there is no obvious progress in terms of response rate (RR) and overall survival (OS); With the great development of molecular biology, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has good therapeutic effect on the NSCLC. But, almost all patients of EGFR-mutant lung cancers develop drug resistance to these agents. This paper reported a case of a 49-year-old woman with lung adenocarcinoma who had EGFR mutant (19-DEL) treated with EGFR-TKIs. After disease progression, histological examination of a secondary biopsy specimen revealed small cell lung cancer (SCLC) had transformed to SCLC treatment. Through the analysis of the process and effect of her therapy, the following is a summary of the relevant mechanism.
The First Department of Lung Cancer, Xinjiang Tumor Hospital, Urimuqi 830000, China.
Shuping
S
Xue
The First Department of Lung Cancer, Xinjiang Tumor Hospital, Urimuqi 830000, China.
Tingting
T
Yu
The First Department of Lung Cancer, Xinjiang Tumor Hospital, Urimuqi 830000, China.
Yan
Y
Zhang
The First Department of Lung Cancer, Xinjiang Tumor Hospital, Urimuqi 830000, China.
Li
L
Shan
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D000077192:Adenocarcinoma of Lung; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors